Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

This study is testing a combination of three cancer drugs — cetuximab, irinotecan, and toripalimab — for people with advanced colorectal cancer that started in the right side of the colon and has spread to other parts of the body. Researchers want to see if this triple-drug approach works better for patients whose tumors have specific genetic characteristics. **You may be eligible if...** - You have been diagnosed with colorectal cancer (adenocarcinoma) that originated in the right colon and has spread (metastatic) - Your tumor has been tested and found to be "RAS/BRAF wild-type" (a specific genetic profile) - You have already received prior chemotherapy treatments including bevacizumab, irinotecan, oxaliplatin, and 5-fluorouracil, and your cancer progressed - You have never received anti-EGFR or PD-1 immunotherapy drugs - Your blood counts, liver, and kidney function are within acceptable ranges - You have a reasonable level of physical function (able to care for yourself) **You may NOT be eligible if...** - You have had a heart attack or stroke in the past 6 months - You have uncontrolled infections, severe diabetes, or serious heart problems - You have brain tumors or brain metastases - You have had another cancer in the past 5 years (except certain skin or cervical cancers) - You are pregnant or breastfeeding - You have an active autoimmune disease or history of organ transplant Talk to your doctor to see if this trial is right for you.